Godavari Biorefineries Share Price Gains Over 7% After China Approves Patent for Viral Infection Treatment

Godavari Biorefineries Limited has achieved a significant milestone with the approval of a patent by the Chinese Patent Office, as reported on the exchange filings on September 16, 2026.  

The patent, titled "USE OF COMPOUNDS FOR TREATING VIRAL INFECTIONS," highlights the company's innovative approach in the field of viral infection treatment. 

Patent Details and Scientific Mechanism 

The patent granted by the National Intellectual Property Administration of China is registered under number 9271298, with the application number ZL 2021 8 0048053.9. The application was initially submitted on May 10, 2021, and the official grant was announced on September 15, 2026. 

The invention focuses on the use of specific compounds that inhibit V-ATPase activity within cells. These compounds are designed to be manufactured into medicaments for treating viral infections, showcasing a targeted biochemical approach. 

Inventor and Corporate Filing Information 

The patent credits inventors M. Athawal, S. Gawad, P. Kaka, and S. Srivastava for their contributions. The patent validation was authorised by Commissioner Shen Changyu.  

This development was formally communicated to the National Stock Exchange of India Limited and BSE Limited on September 16, 2026, under the stock symbol GODAVARIB and scrip code 544279. 

Read More: Oracle Starts Fresh Layoffs After 21,000 Employee Workforce Reduction in Fiscal Year 2026! 

About Godavari Biorefineries 

Godavari Biorefineries Limited is a leading Indian integrated biorefinery that produces bio-based chemicals, ethanol, sugar, and green power from renewable resources like sugarcane. 

Godavari Biorefineries Share Price Performance 

As of September 16, 2026, at 11:34 AM, Godavari Biorefineries share price on NSE was trading at ₹243.62, up by 7.50% from the previous closing price. 

Conclusion 

Godavari Biorefineries Limited's patent approval in China for viral infection treatment compounds marks a pivotal development. The patent, filed under number 9271298, was officially granted on September 15, 2026, following its initial submission on May 10, 2021. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.